Letters to the Editor

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville
Public Health Science Division, Fred Hutchinson Cancer Center, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Department of Medicine, Residency Program, University of Washington, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA
Haematologica Early view Sep 22, 2022 https://doi.org/10.3324/haematol.2022.281631